Coronavirus
WHO to secure initial COVID-19 vaccine for 20% of Africans
According to WHO, this initial batch will cover 20% of the African population.

Published
8 months agoon

The World Health Organization (WHO) has moved to secure an initial 230 million doses of Covid-19 vaccines for Africa, while also advocating that any vaccine in development should also be tested on the continent.
This is as the African continent hopes to benefit from the global vaccine allocation plan, known as COVAX, which aims to help purchase and distribute equitably, 2 billion doses of approved vaccines by the end of 2021.
The disclosure was made by the programme area manager for WHO Africa, Richard Mihigo, to an online news conference.
READ: Buhari sheds light on why Magu was suspended
Mr. Mihigo said, “This (initial batch) will cover 20% of the African population, initially prioritizing those who are the front line, health care workers, then expanding to cover vulnerable groups.’’
It can be recalled that during an interview with Reuters, the Chief Executive Officer of GAVI vaccine alliance, Seth Berkley, said 76 wealthy countries have committed to joining a global Covid-19 vaccine allocation plan, which is co-led by the WHO.
The scheme has 9 Covid-19 vaccine candidates covering a range of technologies and scientific approaches. Some of them are in the final stage of clinical trials and could have data available by the end of the year.
READ: WHO is concerned that vaccine hoarding could prolong pandemic
The Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), Richard Hatchett, disclosed that only 2 of the potential Covid-19 vaccines are being tested in Africa. The CEPI, co-leads the COVAX project with the WHO and the Gavi vaccines alliance.
He said, “Testing vaccines on the continent ensures that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates for the African population so they can be confidently rolled out in Africa.’’
The head of the Africa Centres for Disease Control and Prevention, John Nkengasong, explained in an online news conference that talks with COVAX would supplement other negotiations with countries like China, Canada and the United States over securing access to shots
Chike Olisah is a graduate of accountancy with over 15 years working experience in the financial service sector. He has worked in research and marketing departments of three top commercial banks. Chike is a senior member of the Nairametrics Editorial Team. You may contact him via his email- [email protected]


Coronavirus
FG explains how the Covid-19 vaccines work and their composition
The NPHCDA Director said that Covid-19 vaccine candidates are of various categories based on their mechanism of action.

Published
12 hours agoon
April 20, 2021
The Federal Government through the National Primary Health Care Development Agency (NPHCDA) has explained the composition of the Covid-19 vaccines and how they work.
This is as some of them have been approved for emergency use by the World Health Organization (WHO) and some countries, while others are still at different phases of clinical trials for possible approval.
According to a report from the News Agency of Nigeria (NAN), this insight was given by the Executive Director/Chief Executive of NPHCDA, Dr Faisal Shuaib, who said there were several COVID-19 vaccine candidates.
READ: African Union signs deal for 400 million Johnson and Johnson single shot vaccine
He said that Covid-19 vaccine candidates are of various categories based on their mechanism of action such as the inactivated or weakened virus vaccines.
He explained that the idea behind the formulation of an inactivated or weakened virus vaccine is to elicit an immune response without causing the disease itself. Shuaib also said there were protein-based vaccines, which used harmless fragments of proteins or protein shells that mimic the Covid-19 virus to safely generate an immune response.
He added that the viral vector vaccines used a virus that had been genetically engineered to produce coronavirus proteins to safely generate an immune response and not give rise to the disease.
Going further, Shuaib pointed out that the Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) vaccines employed a cutting-edge approach that used genetically engineered RNA or DNA to generate a protein that safely prompted an immune response.
READ: China publicly presents its COVID-19 vaccines, 2 doses to cost below $146
What you should know
- It can be recalled that on March 2, 2021, Nigeria received the first set of about 4 million doses of the AstraZeneca Covid-19 vaccine, manufactured by the Serum Institute in India and shipped via the COVAX Facility, a partnership between CEPI, Gavi, UNICEF and WHO.
- A few days ago, the Executive Director of NPHCDA disclosed that a total of 8,491 Nigerians have reacted adversely to the AstraZeneca inoculation since the exercise began on March 15.
- He said that Nigeria recorded 52 cases of moderate to severe incidents of Adverse Effects Following Immunisation (AEFI), presented as fever, vomiting, diarrhoea headaches, dizziness and allergic reactions.
- About 1.09 million Nigerians have so far been administered the first dose of the AstraZeneca Covid-19 vaccine.
Business News
COVID-19 Update in Nigeria
On the 19th of April 2021, 70 new confirmed cases were recorded in Nigeria.

Published
23 hours agoon
April 20, 2021
The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 164,303 confirmed cases.
On the 19th of April 2021, 70 new confirmed cases were recorded in Nigeria.
To date, 164,303 cases have been confirmed, 154,384 cases have been discharged and 2,061 deaths have been recorded in 36 states and the Federal Capital Territory.
A total of 1.84 million tests have been carried out as of April 17th, 2021 compared to 1.81 million tests a day earlier.
COVID-19 Case Updates- 19th April 2021,
- Total Number of Cases – 164,303
- Total Number Discharged – 154,384
- Total Deaths – 2,061
- Total Tests Carried out – 1,838,174
According to the NCDC, the 70 new cases were reported from 5 states- Lagos (27), Kaduna (16), Ondo (16), Yobe (6), and Bauchi (5).
Meanwhile, the latest numbers bring Lagos state total confirmed cases to 58,119, followed by Abuja (19,756), Plateau (9,035), Kaduna (9,014), Rivers (7,060), Oyo (6,839), Edo (4,897), Ogun (4,639), Kano (3,942), Ondo (3,226), Kwara (3,120), Delta (2,617), Osun (2,572), Nasarawa (2,380), Enugu (2,281), Katsina (2,097), Gombe (2,034), Ebonyi (2,020), Anambra (1,909), Akwa Ibom (1,843), and Abia (1,683).
Imo State has recorded 1,655 cases, Bauchi (1,540), Borno (1,337), Benue (1,188), Adamawa (1,063), Niger (930), Taraba (910), Bayelsa (885), Ekiti (869), Sokoto (775), Jigawa (527), Kebbi (450), Cross River (394), Yobe (365), Zamfara (240), while Kogi state has recorded 5 cases only.
READ ALSO: COVID-19: Western diplomats warn of disease explosion, poor handling by government
Lock Down and Curfew
In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.
The movement restriction, which was extended by another two weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.
On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.
On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.
Governor Babajide Sanwo-Olu of Lagos State announced the closed down of the Eti-Osa Isolation Centre, with effect from Friday, 31st July 2020. He also mentioned that the Agidingbi Isolation Centre would also be closed and the patients relocated to a large capacity centre.
Due to the increased number of covid-19 cases in Nigeria, the Nigerian government ordered the reopening of Isolation and treatment centres in the country on Thursday, 10th December 2020.
On 26th January 2021, the Federal Government announced the extension of the guidelines of phase 3 of the eased lockdown by one month following the rising cases of the coronavirus disease in the country and the expiration of phase 3 of the eased lockdown.
On 28th February 2021, the federal government confirmed that the first tranche of Covid-19 vaccines will arrive in Nigeria on Tuesday, March 2nd, 2021.
On Tuesday, 2nd March 2021, the National Primary health Care Development Agency announced the arrival of the expected COVX Astrazeneca/Oxford covid-19 vaccines.
On Saturday, 6th March 2021, President Muhammadu Buhari and his vice, Yemi Osinbajo received vaccination against the covid-19 as the State House in Abuja.
READ ALSO: Bill Gates says Trump’s WHO funding suspension is dangerous
Nairametrics | Company Earnings
Access our Live Feed portal for the latest company earnings as they drop.
- 2020 FY Results: Guinea Insurance Plc reports a loss of N227.7 million.
- 2020 FY Results: Unity Bank Plc posts profit after tax of N2.09 billion.
- Guinea Insurance Plc reports a loss of N142.13 million in 9M 2020.
- Unilever Nigeria Plc set to hold Annual General Meeting on 6th of May.
- UBA Plc posts profit after tax of N38.16 billion in Q1 2021.
-
Get the scoops and market intelligence that can help
you make better investment decisions right in your
mailbox.